EXPRESSION OF THE RENIN-ANGIOTENSIN SYSTEM COMPONENTS IN ONCOLOGIC DISEASES

Acta Clin Croat. 2019 Jun;58(2):354-364. doi: 10.20471/acc.2019.58.02.21.

Abstract

The literature devoted to changes in the expression of the renin-angiotensin system (RAS) proteins of cancer cells was analyzed. The dynamics of RAS protein expression in malignant tumors and the possible role of epigenetic mechanisms in these processes are briefly reviewed. Through research of the epigenetic mechanisms in cancer, principally new techniques for their correction based on the use of selective regulatory systems of covalent modification of histone proteins (for example, deacetylase inhibitor) and microRNA synthesis technologies have been developed. Literature data show promising pharmacological correction of epigenetic modification of chromatin in the treatment of cancer.

Keywords: Ectopic RAS cancer cells; Epigenetic stimulation of RAS in oncology; Oncology.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Angiotensins / genetics
  • Animals
  • Epigenesis, Genetic*
  • Humans
  • Neoplasms / genetics*
  • Peptidyl-Dipeptidase A / genetics*
  • Receptor, Angiotensin, Type 1 / genetics*
  • Receptor, Angiotensin, Type 2 / genetics*
  • Renin / genetics
  • Renin-Angiotensin System / genetics*

Substances

  • Angiotensins
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2
  • Renin